We’re pleased to welcome Patricia Drake as our new Chief Commercial Officer. To read more, go to https://lnkd.in/eFRjcgVQ
About us
Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc., is a biopharmaceutical company developing and delivering innovative therapies in critical care and infectious disease. Our approved treatments are indicated for use in life-threatening circumstances for seriously ill patients, and our investigational therapies are in development for patients fighting drug-resistant pathogens. Growing antimicrobial resistance to existing therapies represents an urgent threat to global public health, and is directly related to significant mortality rates and longer, more expensive hospital stays. We are proud to work with physicians, nurses, hospital pharmacists and administrators, and all who devote their time to caring for patients.
- Website
-
https://innovivaspecialtytherapeutics.com/
External link for Innoviva Specialty Therapeutics, Inc.
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Waltham, MA
- Type
- Privately Held
- Founded
- 2023
- Specialties
- Cardiovascular and Anti-infectives
Locations
-
Primary
Get directions
35 Gatehouse Drive
Waltham, MA 02451, US
Employees at Innoviva Specialty Therapeutics, Inc.
Updates
-
We are excited to announce the launch of four new antimicrobial drug susceptibility testing medical devices with our partner, Thermo Fisher Scientific. Together, we are working to bring the latest advances in susceptibility testing technology to ensure flexibility, accuracy, and consistency in the lab. #microbiology, #antibiotic resistance, #IST
-
-
Read about how we are addressing important challenges and creating new opportunities to enhance patient care in critical care and infectious disease in the June issue of Biopharma Dealmakers. https://lnkd.in/eaSY_PPh
-
-
Matthew Ronsheim, PhD, President of Innoviva Specialty Therapeutics, is excited to announce that the National Medical Products Administration (NMPA) of China has approved XACDURO for the treatment of hospital-acquired and ventilator-associated pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex in patients 18 years of age and older. Read more details here: https://lnkd.in/e8dRvvTs
-
-
Teamwork is critical in our industry. That’s why we are heading to the annual NTI conference in Denver to share our insights and learn first-hand about the latest issues critical care nurses face daily. Together, we can address the most urgent challenges to improving patient outcomes. #ISTX #NTI2024 #nurses #criticalcare.
-